Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 15, 2017Proceedings of the National Academy of SciencesOpen Access

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

View Full Paper
Ask AI
Bookmark
Share

Authors

RJRinath JeselsohnHarvard UniversityMCMacIntosh CornwellBrigham and Women's HospitalMPMatthew PunDuke University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Jeselsohn et al. (2017) studied this question.

synapsesocial.com/papers/6a227108ffccceb004b714e1https://doi.org/10.1073/pnas.1620993114
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer2003 · 1,833 citations
  2. 2The versatile functions of Sox9 in development, stem cells, and human diseases2014 · 384 citations
  3. 3Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles2005 · 58,218 citations
  4. 4Endogenous Purification Reveals GREB1 as a Key Estrogen Receptor Regulatory Factor2013 · 428 citations
  5. 5GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility2012 · 396 citations